LBRX
LB Pharmaceuticals Inc Common Stock
1W: -8.4%
1M: -2.9%
3M: +23.4%
YTD: +15.0%
$23.53
-0.46 (-1.92%)
After Hours: $26.12 (+2.59, +11.03%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$595.3M
52W Range13.36-27.55
Volume467,224
Avg Volume233,766
Beta-5.92
Dividend—
Analyst Ratings
Company Info
CEOHeather D. Turner
Employees16
SectorHealthcare
IndustryBiotechnology
IPO Date2025-09-11
Websitelbpharma.us
One Pennsylvania Plaza
New York, NY 10119
US
New York, NY 10119
US
212 605 0300
About LB Pharmaceuticals Inc Common Stock
Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.
Latest News
LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors
LB Pharmaceuticals to Participate in Upcoming March Investor Events
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
LB Pharmaceuticals Announces $100.0 Million Private Placement
LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development Program
Recent Insider Trades
No insider trades found